Following sequencing on the NextSeq® or HiSeq® instruments, TruSight Tumor 170 offers push-button variant calling. The analytical sensitivity and specificity of TruSight Tumor 170 was assessed on 95 unique samples (each in duplicates), including FFPE samples of varying quality from multiple tissue types, reference standards, and cell line and FFPE mixes. We demonstrate the TruSight Tumor 170 is able to detect multiple variant types within a single sample at low nucleic acid input, while exhibiting high sensitivity and specificity for low allele fraction detection.

**DNA Workflow**

- 2-day flexible workflow
- Low input requirements
- GMP (Good Manufacturing Practice) manufactured probes for 170 genes
- Variant calling optimized for FFPE-extracted nucleic acid
- Target ≥95% specificity and sensitivity for copy number variants at a target ≥95% sensitivity and specificity with small variants at 5% allele fraction
- Variant calling optimized for FFPE-extracted nucleic acid
- Target ≥95% specificity and sensitivity for small DNA variants, composed of 530 SNVs, 80 indels (including 43 CNVs), 43 small insertions and deletions (indels), 106 small DNA variants, and 523 small CNVs

**Copy Number Variation (CNV) Calling**

- Target ≥95% specificity and sensitivity for CNVs
- No CNV called in 24 normal samples (in duplicates)
- Overall specificity 99.97% 99.96%
- Overall sensitivity 99.99% 100.00%

**Conclusion**

TruSight Tumor 170 can achieve high sensitivity and specificity for the detection of somatic variants (small variants and CNVs) from DNA extracted from FFPE tissues.

For Research Use Only. Not for use in diagnostic procedures.